Table 3.
Cox proportional hazards multivariate analysis of predictors for survival in the validation cohort.*
| Variable | HR (95% CI) | p-value |
|---|---|---|
| NLR | ||
| ≤3.6 | 1.0 | – |
| >3.6 | 2.19 (1.14–4.21) | 0.018 |
| Age | 0.99 (0.95–1.03) | 0.69 |
| Gender | ||
| Male | 1.0 | – |
| Female | 0.37 (0.19–0.72) | 0.003 |
| T-stage† | ||
| T1a | 1.0 | – |
| T1b | 1.18 (0.46–3.01) | 0.73 |
| T2a | 2.25 (0.87–5.84) | 0.10 |
| T2b | 16.77 (2.21–127.51) | 0.006 |
| T3 | 1.40 (0.38–5.20) | 0.62 |
| T4 | – | – |
| Histology | ||
| SCC | 1.0 | – |
| Adenocarcinoma | 1.05 (0.52–2.09) | 0.90 |
| NSCLC, NOS | 1.40 (0.32–6.07) | 0.65 |
| Total BEDGy10 | 1.01 (0.99–1.02) | 0.47 |
| ECOG | ||
| 0 | 1.0 | – |
| 1 | 1.34 (0.59–3.06) | 0.48 |
| 2 | 0.92 (0.33–2.55) | 0.87 |
| 3 | 0.49 (0.08–3.05) | 0.45 |
| Smoking (pack-years) | 1.00 (0.99–1.01) | 0.98 |
*
Abbreviations: HR – hazard ratio. CI – confidence interval. NLR – neutrophil–lymphocyte ratio. SCC – squamous cell carcinoma. NSCLC, NOS – non-small cell lung cancer, not otherwise specified. BED – biologically effective dose. ECOG – Eastern Cooperative Oncology Group.
†
American Joint Committee on Cancer (AJCC) 7th edition. T4 excluded due to limited sample size.